These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30236065)

  • 1. Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients.
    Hofman JMG; Eisenga MF; Diepenbroek A; Nolte IM; van Dam B; Westerhuis R; Bakker SJL; Franssen CFM; Gaillard CAJM
    BMC Nephrol; 2018 Sep; 19(1):242. PubMed ID: 30236065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
    Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
    Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial.
    Jose A; Mahey R; Sharma JB; Bhatla N; Saxena R; Kalaivani M; Kriplani A
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):54. PubMed ID: 30717690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center.
    Gobbi L; Scaparrotta G; Rigato M; Cattarin L; Qassim L; Carraro G; Rossi B; Calò LA
    Ther Apher Dial; 2020 Dec; 24(6):642-647. PubMed ID: 32154642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
    Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic impact of ferric carboxymaltose in haemodialysis patients].
    Aiello A; Berto P; Conti P; Panichi V; Rosati A
    G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis.
    Bertani L; Tricò D; Zanzi F; Baiano Svizzero G; Coppini F; de Bortoli N; Bellini M; Antonioli L; Blandizzi C; Marchi S
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33673371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis.
    Lacquaniti A; Gargano R; Campo S; Casuscelli di Tocco T; Schifilliti S; Monardo P
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374275
    [No Abstract]   [Full Text] [Related]  

  • 19. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
    Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
    Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
    Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.